Qube Research & Technologies (QRT)’s Denali Therapeutics DNLI Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-590,314	Closed	-$9.75M	–	3641
2025 Q4	$9.75M	Buy	590,314 +362,324	+159%	+$6.12M	0.01%	1365
2025 Q3	$3.31M	Buy	+227,990	New	+$3.28M	﹤0.01%	1983
2025 Q2	–	Sell	-288,221	Closed	-$3.92M	–	3632
2025 Q1	$3.92M	Sell	288,221 -23,286	-7%	-$446K	﹤0.01%	1662
2024 Q4	$6.35M	Buy	+311,507	New	+$7.97M	0.01%	1356
2024 Q2	–	Sell	-37,749	Closed	-$775K	–	3998
2024 Q1	$775K	Sell	37,749 -133,513	-78%	-$2.51M	﹤0.01%	2292
2023 Q4	$3.68M	Buy	171,262 +157,709	+1,164%	+$3.12M	0.01%	1199
2023 Q3	$280K	Buy	+13,553	New	+$344K	﹤0.01%	2281

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qube Research & Technologies (QRT)'s DNLI Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 590,314 shares — an estimated $9.75M sold.

Qube Research & Technologies (QRT) first reported a position in DNLI in Q3 2023 and held it in 7 quarters. The position peaked at $9.75M in Q4 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Qube Research & Technologies (QRT) reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 590,314 Denali Therapeutics shares in Q1 2026, an estimated $9.75M.
Qube Research & Technologies (QRT) first reported a position in Denali Therapeutics in Q3 2023 and held it in 7 quarters.
Qube Research & Technologies (QRT)'s Denali Therapeutics position peaked at $9.75M in Q4 2025.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.